ORKA-001 Phase 1 results presented at EADV show potential for once-per-year dosing, higher efficacy and off-treatment remission Over $500M cash and equivalents provides runway over one year past three key readouts: ORKA-001 Phase 2a and 2b (EVERLAST-A and -B), and ORKA-002 Phase 2 ORKA-002 Phase 1 trial ongoing, with data to be presented around YE 2025 ORKA-001 Phase 2a trial enrolling well with data expected 2H 2026 MENLO PARK, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) — Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis (PsO), today reported third quarter 2025 financial results and provided a corporate update. “We had a very successful quarter where we released our...

Bank continues to champion financial discipline and initiatives that strengthen the local community LAKEWOOD, Colo., Nov. 12, 2025 (GLOBE NEWSWIRE) — FirstBank, one of the nation’s largest privately held banks with a focus on “banking for good,” announced financial results for the third quarter ending September 30, 2025. The bank reported the following:Net income was $216.4 million Total deposits were $23.2 billion Net loans were $16 billion Total assets were $26.7 billionFirstBank’s net income experienced a 37 percent increase year-over-year from $157.65 million in Q3 2024 to $216.42 million in Q3 2025. In addition, the bank announced an agreement to be acquired by PNC one of the largest diversified financial institutions in the U.S. The transaction, which remains subject to regulatory approvals and customary closing conditions,...

The Board of Directors has today approved the interim report for the period 1 January – 30 September 2025. COPENHAGEN AIRPORTS A/SP.O. Box 74Lufthavnsboulevarden 6DK-2770 Kastrup Contact:Rasmus LundCFO Telephone: +45 32312800E-mail: cphpresse@cph.dkwww.cph.dkCVR no. 14 70 72 04AttachmentsInterim report of Copenhagen Airports A-S (CPH) for the period 1 January – 30 September 2025Q3 2025 Interim Report of Copenhagen Airports UK

ALK delivers 18% global organic revenue growth with operating profit up 41% in Q3 Results were better than expected, driven by a strong momentum for tablets, adrenaline autoinjectors, and SCIT/SLIT-drops. Operating profit increased as sales growth, improved gross margin, and optimisations yielded a profit margin of 28%. The full-year outlook has been upgraded.     Q3 performance highlights Comparative figures for Q3 2024 are shown in brackets. Growth rates are stated in local currencies (l.c.), unless otherwise indicated.Total revenue increased by 18% to DKK 1,530 million (1,313) on double-digit sales growth in all regions.     Tablet sales grew by 17% to DKK 737 million (634), on higher volumes. Europe and North America delivered growth of 23% and 20%, respectively. International markets reported a 4% decrease and was impacted by phasing...

COMPANY ANNOUNCEMENT NO 56/2025 – November 12, 2025EBIT up 15% in Q3 driven by solid commercial performance and margin expansion Key Highlights Q3 2025Market share gains and solid commercial performance, driven by our long-term focus on growth categories Reported net revenue growth of 5.3% in Q3 (4.2% YTD) Solid margin expansion and EBIT growth of 15.1% in Q3 (12.6% YTD) Strong Q3 performance in our key Finnish market, following a soft Q2 due to cold weather Earnings per share increased by 20.4% in Q3, driven by stronger profitability Free cash flow increased by 9.5% in Q3 and continues to track in line with our plans We now expect to deliver full-year EBIT growth at the high end of the 8-12% rangeCEO Lars Jensen comments: “We delivered a strong third quarter with 15% EBIT growth, driven by solid margin expansion and...

Quarterly Revenue Up 49% Year-over-Year Positioned to Capitalize on Tape Storage Resurgence and Data Growth Megatrend Debt-Free, Profitable, and Uplisting-Ready with Expanding Strategic Opportunities CAMARILLO, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) — Qualstar Corporation (OTC: QBAK), a trusted provider of scalable data storage and high-efficiency power solutions, today reported financial results for the third quarter ended September 30, 2025. The third quarter of 2025 reflected strong execution and accelerating demand for Qualstar’s tape-storage systems. With no debt, consistent profitability, and growing visibility across global customers and partners, Qualstar is well-positioned to scale both organically and through strategic initiatives as the data-storage industry enters a new era of growth. Third Quarter 2025 Financial HighlightsRevenue...

Continued advancement toward Phase 2/3 clinical trial initiation, on track for the first half of 2026 New preclinical data demonstrated SIL204’s exceptional efficacy across multiple human cancer cell lines, highlighting potential effectiveness against five KRAS-driven cancer types Successfully raised over $9 million during the third quarter, significantly strengthening the Company’s balance sheet Grand Cayman, Cayman Islands, Nov. 12, 2025 (GLOBE NEWSWIRE) — Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company developing RNA interference (RNAi) therapies for KRAS-driven cancers, today reported its financial results for the third quarter ended September 30, 2025, and provided an update on recent business developments. Recent Milestones & Business...

– Recruitment ongoing for Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD; expect to report topline data from both studies in 1H26 – – New Drug Application for rademikibart for the treatment of atopic dermatitis submitted by Simcere, the Company’s exclusive licensee in Greater China, was accepted by China’s NMPA – – Completed termination of American Depositary Receipt program and directly listed our ordinary shares on Nasdaq – – Presented positive data at ERS 2025 supporting the potential of rademikibart to deliver differentiated efficacy and safety in patients across a broad range of baseline type 2 inflammatory markers – SAN DIEGO, Nov. 12, 2025 (GLOBE NEWSWIRE) — Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company...

Third quarter 2025 revenue totaled approximately $18.7 million, an increase of 292% year-over-year and 62% sequentially Company is reiterating revenue guidance for 2026 of $225 million Conference call today at 5:00 p.m. ET BARTLETT, Tenn., Nov. 12, 2025 (GLOBE NEWSWIRE) — SurgePays, Inc. (Nasdaq: SURG) (“SurgePays” or the “Company”), a wireless and fintech technology company connecting subprime and underserved consumers to essential mobile and financial services, today announced revenue growth of 292% year-over-year and 62% sequentially to $18.7 million for the third quarter ended September 30, 2025. The Company is reiterating revenue guidance of $225 million for 2026. “The 2025 third quarter represented an important inflection point for our multi-channel growth platform, which yielded revenue growth of 292% year-over-year and...

Cloud and SaaS revenue increased 9.4% compared with the prior year period, reflecting a continued shift toward recurring, platform-based offerings ENCINO, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) — NETSOL Technologies, Inc. (Nasdaq: NTWK), a provider of AI-powered solutions and services enabling OEMs, dealerships and financial institutions to sell, finance and lease assets, reported results for the fiscal first quarter of 2026 ended September 30, 2025. Fiscal First Quarter 2026 Financial Results Total net revenues for the first quarter of fiscal 2026 increased 2.8% to $15 million, compared with $14.6 million in the prior year period, driven by a 9.4% increase in subscription and support revenues. On a constant currency basis, total net revenues were $15.1 million.Total subscription (SaaS and Cloud) and support revenues increased...